Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone508-767-3861
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$140,000.00
Profitability
Miscellaneous
Employees9
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable
Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions
What is Phio Pharmaceuticals' stock symbol?
Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."
How were Phio Pharmaceuticals' earnings last quarter?
Phio Pharmaceuticals Corp (NASDAQ:PHIO) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.08) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). View Phio Pharmaceuticals' Earnings History.
When is Phio Pharmaceuticals' next earnings date?
Has Phio Pharmaceuticals been receiving favorable news coverage?
Media stories about PHIO stock have trended very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Phio Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Phio Pharmaceuticals.
Are investors shorting Phio Pharmaceuticals?
Phio Pharmaceuticals saw a drop in short interest in January. As of January 31st, there was short interest totalling 18,200 shares, a drop of 94.9% from the January 15th total of 355,600 shares. Based on an average daily volume of 34,900 shares, the short-interest ratio is presently 0.5 days. Currently, 2.8% of the company's shares are short sold. View Phio Pharmaceuticals' Current Options Chain.
Who are some of Phio Pharmaceuticals' key competitors?
Some companies that are related to Phio Pharmaceuticals include PDS Biotechnology (PDSB), Tetraphase Pharmaceuticals (TTPH), X T L Biopharmaceuticals (XTLB), International Stem Cell (ISCO), Acura Pharmaceuticals (ACUR), Melinta Therapeutics (MLNT), Novus Therapeutics (NVUS), Sonoma Pharmaceuticals (SNOA), iCo Therapeutics (ICOTF), GT Biopharma (GTBP), Reliv International (RELV), DelMar Pharmaceuticals (DMPI), BENITEC BIOPHAR/S (BNTC), Capricor Therapeutics (CAPR) and Praxsyn (PXYN).
What other stocks do shareholders of Phio Pharmaceuticals own?
Who are Phio Pharmaceuticals' key executives?
Phio Pharmaceuticals' management team includes the folowing people:
- Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres & CEO (Age 44)
- Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 33)
Who are Phio Pharmaceuticals' major shareholders?
Phio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (121.90%), Renaissance Technologies LLC (51.45%) and UBS Group AG (7.00%).
Which institutional investors are buying Phio Pharmaceuticals stock?
PHIO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, SG Americas Securities LLC and UBS Group AG.
How do I buy shares of Phio Pharmaceuticals?
Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Phio Pharmaceuticals' stock price today?
One share of PHIO stock can currently be purchased for approximately $3.25.
How big of a company is Phio Pharmaceuticals?
Phio Pharmaceuticals has a market capitalization of $2.11 million and generates $140,000.00 in revenue each year. The company earns $-7,360,000.00 in net income (profit) each year or ($57.14) on an earnings per share basis. Phio Pharmaceuticals employs 9 workers across the globe.View Additional Information About Phio Pharmaceuticals.
What is Phio Pharmaceuticals' official website?
How can I contact Phio Pharmaceuticals?
Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]
MarketBeat Community Rating for Phio Pharmaceuticals (NASDAQ PHIO)
MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
